Figure 5From: HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapyHER2 and TOP2A profiling for gene status, RNA and protein expression in adjuvantly treated breast carcinomas. Green cells: non-amplified, low mRNA expression, negative protein expression; Red cells: gene amplification, high mRNA expression, protein positivity. HER2 mRNA and protein expression exhibit different positivity patterns in comparison to TOP2A mRNA and TopoIIa protein expression. The majority of tumors with high TOP2A mRNA expression (112/121 [95.6%]) and the majority of tumors positive for TopoIIa protein expression (145/158 [91.8%]) were not amplified.Back to article page